LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Open

SectorHealthcare

602.82 1.37

Buy Sell

Overview

Share price change

24h

Current

Min

596.96

Max

614.35

Key metrics
By Trading Economics
Income	-72M -114M
Sales	74M 287M
EPS	-4.956
Profit margin	-39.75
Employees	528
EBITDA	-68M -106M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+3.73% upside

Market Stats
By TradingEconomics
Market Cap	4.5B 14B
Previous open	601.45
Previous close	602.82

News Sentiment

By Acuity

33%

67%

83 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

23 gru 2025, 15:21 UTC

Earnings

Correction to Home Depot Outlook Headline on Dec. 9

23 gru 2025, 23:54 UTC

Market Talk

Gold Climbs Above $4,500/oz for First Time Amid Rising Geopolitical Tensions -- Market Talk

23 gru 2025, 23:40 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

23 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23 gru 2025, 21:21 UTC

Acquisitions, Mergers, Takeovers

St Barbara to Use Deposit Toward A$370 Million Subscription to Buy 50% of Simberi Unit

23 gru 2025, 21:20 UTC

Acquisitions, Mergers, Takeovers

St Barbara to Hold Deposit in Escrow

23 gru 2025, 21:20 UTC

Acquisitions, Mergers, Takeovers

St Barbara: Deposit Represents Progress on Lingbao's Strategic Investment in Simberi Mine

23 gru 2025, 21:19 UTC

Acquisitions, Mergers, Takeovers

St Barbara Receives A$32 Million Deposit From Lingbao Gold

23 gru 2025, 21:13 UTC

Acquisitions, Mergers, Takeovers

ServiceNow Bets on Cybersecurity to Boost Growth -- Analysis

23 gru 2025, 20:16 UTC

Market Talk

Oil Futures Settle Higher on Geopolitical Tensions -- Market Talk

23 gru 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Soars on Colder Weather Outlook -- Market Talk

23 gru 2025, 19:13 UTC

Earnings

Acquisitions, Mergers, Takeovers

Mergers and Acquisitions Soared This Year. 2026 Could Be Even Bigger. -- Barrons.com

23 gru 2025, 18:58 UTC

Market Talk

Gold Has Another Record-Setting Day -- Market Talk

23 gru 2025, 18:32 UTC

Market Talk

U.S. Oil Rig Count Rises By 3 to 409 -- Market Talk

23 gru 2025, 17:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

23 gru 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

23 gru 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

23 gru 2025, 17:09 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Armis Seen as Good Fit for ServiceNow in $7.8B Deal -- Market Talk

23 gru 2025, 16:21 UTC

Market Talk

Monthly Canadian GDP Points to Flat Activity So Far for 4Q -- Market Talk

23 gru 2025, 16:16 UTC

Market Talk

Recent 'Disorderly' Yen Falls Could Justify Intervention -- Market Talk

23 gru 2025, 16:15 UTC

Market Talk

Precious Metals Pare Gains -- Market Talk

23 gru 2025, 16:03 UTC

Acquisitions, Mergers, Takeovers

Erste Group Bank: Closing Expected Around Mid-January

23 gru 2025, 16:03 UTC

Acquisitions, Mergers, Takeovers

Erste Group Bank Also Obtained Regulatory Approvals for 50% Stake in Santander Towarzystwo Funduszy Inwestycyjnych

23 gru 2025, 16:02 UTC

Acquisitions, Mergers, Takeovers

Erste Group Bank Obtained Regulatory Approvals by Polish Regulator KNF for Acquisition of Roughly 49% Controlling Stake in Santander Bank Polska

23 gru 2025, 16:01 UTC

Acquisitions, Mergers, Takeovers

Erste Group Bank Receives Green Light for Acquisition in Poland

23 gru 2025, 15:42 UTC

Acquisitions, Mergers, Takeovers

Telefonica: Agreement is For Sale of Telefonica Tech Business in Colombia, Mexico, Chile

23 gru 2025, 15:42 UTC

Acquisitions, Mergers, Takeovers

Telefonica Doesn't Set Out Financial Details of Divestment

23 gru 2025, 15:41 UTC

Acquisitions, Mergers, Takeovers

Telefonica: Deal Will Allow Focus on Core Markets

23 gru 2025, 15:40 UTC

Acquisitions, Mergers, Takeovers

Telefonica To Sell Telefonica Tech South American Business to Hiberus

23 gru 2025, 15:19 UTC

Market Talk

Fixed-Income Traders Misread Underlying Strength of Canada Economy -- Market Talk

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

3.73% upside

12 Months Forecast

Average 624.67 USD 3.73%

High 900 USD

Low 527 USD

Based on 11 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

83 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.